Sigrid Therapeutics Surpasses the 50% Enrollment Milestone in its Clinical Trial, SHINE, to Evaluate the SiPore21® Gel for Sustained Diabetes and Obesity Control
· SHINE is the largest ongoing clinical study of its kind, marking a milestone in research on prediabetes and weight control. It involves individuals who are living with excess weight or obesity and have prediabetes or type 2 diabetes. · SiPore21® Silica "Molecular Sieves" is a promising, non-pharmaceutical oral alternative to injectable drugs for sustainable weight control.Stockholm, April 30th, 2024: Sigrid Therapeutics announced today that it has enrolled more than half of the necessary participants for its clinical trial SHINE of SiPore21®. SHINE is a randomized, double-blind,